Integrative oncogenomic approaches for accelerated cancer-gene discovery

Chin, 1999, Essential role for oncogenic Ras in tumour maintenance, Nature, 400, 468, 10.1038/22788

Felsher, 1999, Reversible tumorigenesis by MYC in hematopoietic lineages, Mol Cell, 4, 199, 10.1016/S1097-2765(00)80367-6

Xue, 2007, Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas, Nature, 445, 656, 10.1038/nature05529

Verna, 1996, 2-Acetylaminofluorene mechanistic data and risk assessment: DNA reactivity, enhanced cell proliferation and tumor initiation, Pharmacol Ther, 71, 83, 10.1016/0163-7258(96)00063-0

Verna, 1996, N-nitrosodiethylamine mechanistic data and risk assessment: bioactivation, DNA-adduct formation, mutagenicity, and tumor initiation, Pharmacol Ther, 71, 57, 10.1016/0163-7258(96)00062-9

Shachaf, 2004, MYC inactivation uncovers pluripotent differentiation and tumour dormancy in hepatocellular cancer, Nature, 431, 1112, 10.1038/nature03043

Wang, 2001, Activation of the Met receptor by cell attachment induces and sustains hepatocellular carcinomas in transgenic mice, J Cell Biol, 153, 1023, 10.1083/jcb.153.5.1023

Harada, 2004, Hepatocarcinogenesis in mice with beta-catenin and Ha-ras gene mutations, Cancer Res, 64, 48, 10.1158/0008-5472.CAN-03-2123

Sandgren, 1989, Oncogene-induced liver neoplasia in transgenic mice, Oncogene, 4, 715

Murakami, 1993, Transgenic mouse model for synergistic effects of nuclear oncogenes and growth factors in tumorigenesis: interaction of c-myc and transforming growth factor alpha in hepatic oncogenesis, Cancer Res, 53, 1719

Deane, 2001, Hepatocellular carcinoma results from chronic cyclin D1 overexpression in transgenic mice, Cancer Res, 61, 5389

Manickan, 2001, Conditional liver-specific expression of simian virus 40 T antigen leads to regulatable development of hepatic neoplasm in transgenic mice, J Biol Chem, 276, 13989, 10.1074/jbc.M009770200

Jhappan, 1990, TGF alpha overexpression in transgenic mice induces liver neoplasia and abnormal development of the mammary gland and pancreas, Cell, 61, 1137, 10.1016/0092-8674(90)90076-Q

Schmitt, 2002, Dissecting p53 tumor suppressor functions in vivo, Cancer Cell, 1, 289, 10.1016/S1535-6108(02)00047-8

Schmitt, 2002, A senescence program controlled by p53 and p16INK4a contributes to the outcome of cancer therapy, Cell, 109, 335, 10.1016/S0092-8674(02)00734-1

Hemann, 2005, Evasion of the p53 tumour surveillance network by tumour-derived MYC mutants, Nature, 436, 807, 10.1038/nature03845

Pear, 1998, Efficient and rapid induction of a chronic myelogenous leukemia-like myeloproliferative disease in mice receiving P210 bcr/abl-transduced bone marrow, Blood, 92, 3780, 10.1182/blood.V92.10.3780

Zender, 2005, Generation and analysis of genetically defined liver carcinomas derived from bipotential liver progenitors, Cold Spring Harb Symp Quant Biol, 70, 251, 10.1101/sqb.2005.70.059

Zender, 2006, Identification and validation of oncogenes in liver cancer using an integrative oncogenomic approach, Cell, 125, 1253, 10.1016/j.cell.2006.05.030

Lucito, 2003, Representational oligonucleotide microarray analysis: a high-resolution method to detect genome copy number variation, Genome Res, 13, 2291, 10.1101/gr.1349003

Kim, 2006, Comparative oncogenomics identifies NEDD9 as a melanoma metastasis gene, Cell, 125, 1269, 10.1016/j.cell.2006.06.008

Maser, 2007, Chromosomally unstable mouse tumours have genomic alterations similar to diverse human cancers, Nature, 447, 966, 10.1038/nature05886

Elledge, 2005, An open letter to cancer researchers, Science, 310, 439, 10.1126/science.310.5747.439b

Davies, 2002, Mutations of the BRAF gene in human cancer, Nature, 417, 949, 10.1038/nature00766